Literature DB >> 27088711

Prolonged Mean Transit Time Detected by Dynamic Susceptibility Contrast Magnetic Resonance Imaging Predicts Cerebrovascular Reserve Impairment in Patients with Moyamoya Disease.

Takayuki Kawano1, Yuki Ohmori, Yasuyuki Kaku, Daisuke Muta, Ken Uekawa, Takashi Nakagawa, Toshihiro Amadatsu, Daiki Kasamo, Shinya Shiraishi, Mika Kitajima, Jun-Ichi Kuratsu.   

Abstract

BACKGROUND: Evaluating cerebrovascular reserve (CVR) is important for patients with moyamoya disease (MMD). 123I-iodoamphetamine single-photon emission CT (SPECT) with acetazolamide (ACZ) challenge is widely carried out, but using ACZ becomes problematic owing to its off-label use and its adverse effects. Here, we report the efficacy of dynamic susceptibility contrast MRI (DSC-MRI) for the evaluation of CVR in MMD patients.
METHODS: All 33 MMD patients underwent both SPECT and DSC-MRI at an interval of <10 days from each other (mean age 38.3 years). The region of interest (ROI) was the anterior cerebral artery (ACA) territory, middle cerebral artery (MCA) territory, basal ganglia and cerebellum hemisphere for cerebral blood flow (CBF), cerebral blood volume (CBV) and mean transit time (MTT) images. The ratios of the ROIs to the ipsilateral cerebellum were calculated for each parameter and evaluated. The CVR was calculated using images acquired by SPECT before and after ACZ administration. The ratios of DSC-MRI parameters and CVR were compared and evaluated for each ROI.
RESULTS: The MTT of the ACA and MCA territories significantly correlated with CVR (p < 0.0001). However, CBF and CBV had no correlation with CVR. The MTT ratio had a threshold of 1.966, with a sensitivity of 68.4% and a specificity of 91.5% for predicting decreased CVR (<10%).
CONCLUSION: MTT had a negative correlation with CVR. DSC-MRI is easy, safe and useful for detecting decreased CVR and can be used as a standard examination in MMD patient's care.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27088711     DOI: 10.1159/000445696

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  8 in total

Review 1.  Progress in moyamoya disease.

Authors:  Shuling Shang; Da Zhou; Jingyuan Ya; Sijie Li; Qi Yang; Yuchuan Ding; Xunming Ji; Ran Meng
Journal:  Neurosurg Rev       Date:  2018-06-18       Impact factor: 3.042

2.  Using arterial spin labeling to measure cerebrovascular reactivity in Moyamoya disease: Insights from simultaneous PET/MRI.

Authors:  Moss Y Zhao; Audrey P Fan; David Yen-Ting Chen; Yosuke Ishii; Mohammad Mehdi Khalighi; Michael Moseley; Gary K Steinberg; Greg Zaharchuk
Journal:  J Cereb Blood Flow Metab       Date:  2022-03-02       Impact factor: 6.960

3.  Standardized acquisition and post-processing of dynamic susceptibility contrast perfusion in patients with brain tumors, cerebrovascular disease and dementia: comparability of post-processing software.

Authors:  Manuel Alexander Schmidt; Michael Knott; Philip Hoelter; Tobias Engelhorn; Elna Marie Larsson; Than Nguyen; Marco Essig; Arnd Doerfler
Journal:  Br J Radiol       Date:  2019-10-24       Impact factor: 3.039

4.  Impact of aberrant cerebral perfusion on resting-state functional MRI: A preliminary investigation of Moyamoya disease.

Authors:  Yituo Wang; Lubin Wang; Penggang Qiao; Fugeng Sheng; Cong Han; Enmao Ye; Yu Lei; Feng Yan; Shanshan Chen; Yuyang Zhu; Guiyun Mi; Gongjie Li; Zheng Yang
Journal:  PLoS One       Date:  2017-04-25       Impact factor: 3.240

5.  Comparative study of MR mTI-ASL and DSC-PWI in evaluating cerebral hemodynamics of patients with Moyamoya disease.

Authors:  Jinge Zhang; Chunchao Xia; Yi Liu; Weiqiang Qian; Wanlin Peng; Keling Liu; Lei Li; Fei Zhao; Zhenlin Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  Moyamoya disease and syndrome: a review.

Authors:  Zeferino Demartini; Bernardo Ca Teixeira; Gelson Luis Koppe; Luana A Maranha Gatto; Alex Roman; Renato Puppi Munhoz
Journal:  Radiol Bras       Date:  2022 Jan-Feb

7.  Acetazolamide-augmented dynamic BOLD (aczBOLD) imaging for assessing cerebrovascular reactivity in chronic steno-occlusive disease of the anterior circulation: An initial experience.

Authors:  Junjie Wu; Seena Dehkharghani; Fadi Nahab; Deqiang Qiu
Journal:  Neuroimage Clin       Date:  2016-11-17       Impact factor: 4.881

8.  Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome.

Authors:  Alessandra D'Amico; Lorenzo Ugga; Sirio Cocozza; Sara Maria Delle Acque Giorgio; Domenico Cicala; Claudia Santoro; Daniela Melis; Giuseppe Cinalli; Arturo Brunetti; Sabina Pappatà
Journal:  Neurol Sci       Date:  2020-07-10       Impact factor: 3.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.